One percent of circulating IgG in humans recognizes galactose al,3 galactose residues (anti-Gal) and is synthesized in response to stimulation by enteric bacteria. In this study, we found that the prevalence of binding of anti-Gal to blood isolates is significantly higher than its binding to normal stool isolates. When anti-Gal bound onto the lipopolysaccharide of a representative blood isolate, Serratia marcescens #21, it blocked its alternative complement pathway (ACP) lysis and made the organism serum resistant. In contrast, when anti-Gal bound to the capsular polysaccharide of a serum sensitive Serratia, #7, it increased ACP killing ofthis strain. The mechanism of blockade of ACP lysis by anti-Gal did not involve a decrease in the number ofC3 molecules deposited onto Serratia #21 or an inhibition of the binding of C3b to its LPS, nor did it change the iC3b and C3d degradation products of bound C3b or prevent membrane attack complex formation on this organism. Our findings suggest that the effect ofanti-Gal on immune lysis is dependent on the bacterial outer membrane structure to which it binds. We postulate that anti-Gal may play a role in the survival of selected Enterobacteriace in Gram-negative sepsis by blocking ACP-mediated lysis of such bacteria by the nonimmune host, and that this effect depends on where anti-Gal finds its epitope on the bacterial outer membrane. (J. Clin.
Introduction
Anti-Gal is a natural polyclonal IgG antibody found in the serum of all humans (1) . It constitutes as much as 1% of the total circulating serum IgG (1) and binds specifically to glycoconjugates bearing a 1,3 terminal digalactose residues (2) . Human cells do not express the Gal a 1,3Gal structure on their surface (3) . However, this epitope has been found on surface glycoconjugates of a number of mammalian cells including mouse (4, 5) , rabbit (6) , and cow (7) cells. Studies of the distribution of anti-Gal and the Gal a 1,3Gal epitope among primates reveals a reciprocal evolutionary pattern (8, 9) . Old World monkeys, apes, and humans have suppressed expression ofthe Gal a 1,3Gal structure, concomitant with the production This is paper No. 47 from the Center for Immunochemistry of the University of California at San Francisco. of anti-Gal. Nonprimate mammals, prosimians, and New World monkeys express this epitope but do not synthesize anti-Gal. Neither the evolutionary pressure that selected Old World primates, including man, for the synthesis of anti-Gal nor the present survival advantage to maintaining this antibody in such high titers is known.
The presence throughout life of anti-Gal in high titers in serum led to the hypothesis that bacteria within the normal intestinal flora provide a constant antigenic stimulation for the synthesis of anti-Gal. This would be analogous with the bacterial stimulus for synthesis of blood group antibodies (10). Indeed, we found that anti-Gal did bind to a number of Escherichia coli, Klebsiella, and Salmonella strains (1 1). Some of these bacteria had been isolated from the bloodstreams of patients and we subsequently found that anti-Gal often bound to Gram-negative human blood isolates. These findings raised intriguing questions about how these organisms could survive in the bloodstream in the presence of such high titers of specific antibody.
In this study, we determined the prevalence of binding of anti-Gal to human blood isolates and compared it to that to normal stool isolates. We then examined the effect on the deposition and degradation of complement components onto two representative Serratia marcescens blood isolates of anti-Gal binding to their surfaces. The two bacteria bound anti-Gal but differed in their sensitivity to killing by normal human serum (NHS)'. We report that bloodstream isolates are significantly more apt to bind anti-Gal than isolates of the same species from the stools oflaboratory volunteers, that anti-Gal does not provide a "protected" site to which C3 can bind, and that when anti-Gal binds to LPS sites, it blocks immune lysis that is activated through the alternative complement pathway (ACP) and makes the organisms serum resistant (Ser). We hypothesize that the blockade of complement-mediated clearance mechanisms by the binding of anti-Gal to their surfaces may allow some bacteria to survive in the bloodstreams of patients with sepsis.
Methods
Bacterial strains and antigens. We studied 90 blood isolates from patients with Gram-negative sepsis who were hospitalized at the Beth Israel (BI) Hospital in Boston, Massachusetts and the Veterans Administration Medical Center (SF VAMC) in San Francisco, California, and 27 Gram-negative facultatively aerobic bacteria isolated from the stools of healthy volunteers from our laboratory in San Francisco. 44 isolates were collected consecutively from blood cultures submitted from July, 1987 through June, 1988 to the SF VAMC Clinical Laboratory and represented all such isolates of which we are aware. An additional blood isolate from the VAMC, S. marcescens #7, has been extensively characterized (12). The remaining strains were selected randomly from a collection of all blood isolates from the BI Clinical Laboratory during 13 consecutive months from May, 1981 to May, 1982, inclusive. We already have characterized S. marcescens #21 from the BI collection (12).
LPS and capsular polysaccharides (K) were extracted from Serratia #21 and #7 following established methods (12) (13) (14) .
Purification ofanti-Gal. Anti-Gal was isolated by affinity chromatography from plasma of healthy individuals with blood type AB, as described previously (15) . Batches of 50 ml of heat-inactivated plasma were loaded onto a 20-ml affinity chromatography SYNSORB column to which the oligosaccharide epitope Gal a1,3Gal #31,4GlcNAc (Chembiomed Ltd., Edmonton, Alberta, Canada) had been conjugated. After extensive washing with PBS, the column-bound antibodies were eluted with 0.5 M melibiose (Sigma Chemical Co., St. Louis, MO) in PBS and dialyzed against PBS. The final anti-Gal concentration was brought to 100 gg/ml, a concentration equivalent to that in NHS (15) . Serum anti-Gal is normally exclusively IgG (16) ; we confirmed that the eluted antibody was IgG by radial immunodiffusion (Behring, Marburg, FRG) . The reactivity ofthe purified anti-Gal was assessed as described previously (1) by testing the ability ofthis IgG to agglutinate rabbit red blood cells (RRBCs) that express abundant a-galactosyl residues on their surface. Preparation ofanti-Gal depleted NHS (Gal-NHS). NHS was depleted of anti-Gal (Gal-NHS) by passing it repeatedly through the SYNSORB column. This was done with fresh NHS and at 40C to preserve complement activity. The anti-Gal-depleted serum lost 10% of normal ACP hemolytic activity (17) . Gal-NHS lost its ability to agglutinate RRBCs (1) . Dot blot assay. This assay was performed as described by our laboratory (18) . Briefly, we dotted organisms grown on Mueller-Hinton (M-H) agar onto pieces of nitrocellulose paper, which were then air dried. We then incubated the nitrocellulose, first in a 1% casein solution for 30 min and then with anti-Gal (2 Isg/ml in casein solution) for 2 h.
Papers were washed with PBS and reacted for 1 h with an alkaline phosphatase-conjugated goat anti-human IgG (Vector Laboratories, Burlingame, California), as secondary antibody. The blots were then developed with a substrate solution that contained naphthol (1 mg/ml) and Fast Red TR salt (2 mg/ml) (Sigma Chemical Co.) in 50 mM Tris buffer (pH = 8). Control blots were included that had on them only: (a) M-H agar without bacteria; (b) bacteria and secondary antibody but no anti-Gal; and (c) alkaline phosphatase substrate but no antibody. We repeated the assay three times for each organism and recorded the results as positive when a red color was clearly visible as compared with controls, and this result occurred in at least two ofthe three assays. Two independent observers recorded the results. Bactericidal assay. We used a standard bactericidal assay (19). Serratia #21 and #7 were grown overnight on Mueller-Hinton agar, transferred to a flask containing M-H broth, and incubated at 37°C in a shaking water bath. When the cultures had reached an absorbance at wavelength 640 (A640) of 0.6, the bacteria were pelleted and resuspended to an Aw of 0.6 in either veronal-buffered saline (VBS) with 0.5% BSA or VBS containing 1 mM MgCl2 and 0.15 mM CaCl2 (VBS++) with 0.5% BSA. They were then diluted 1:35,000 in the same buffer. This dilution of bacteria had -104 CFU/ml. Reaction mixtures were prepared by combining equal volumes of the diluted bacterial suspension and a test serum that contained intact complement systems. We tested the following sera: (a) aliquots of NHS; (b) Gal-NHS; (c) hypogammaglobulinemic serum (hypoey serum) that contained < 10% of normal immunoglobulin levels and, in particular, < 5-1l0% of normal anti-Gal levels; (d) serum obtained from a patient with congenital properdin deficiency (P-serum) that had no measurable ACP activity (20) ; (e) P-serum absorbed at 0C with the test strain for three sequential 30-min periods. These absorptions were performed by resuspending the organism to an Aw of 1 and pelleting it. Serum was then added in a volume equal to twice the bacterial pellet (serum:bacterial pellet ratio = 2).
When the effect of anti-Gal was being assessed, anti-Gal (100 jig/ ml) was added to the reaction mixture in a volume equal to that ofthe test serum. In experiments that assessed the inhibitory effects ofcarbohydrates, anti-Gal (100 Mg/ml) and the inhibitor, either a methyl galactoside, lactose, or sucrose, at 0.1 M final concentrations, were simultaneously added to the reaction mixture in equal volumes to the test serum.
In some assays, the test serum was chelated with 10 mM EGTA containing 10 mM MgCl2 (MgEGTA) to block activation ofthe classical complement pathway while allowing alternative pathway activation to proceed. VBS instead of VBS++ was used in these assays.
In all these experiments, sufficient VBS or VBS++ was added to each reaction mixture to bring the final reaction mixture volume to 125
Ml. The final serum concentration was 20% unless indicated otherwise.
The reaction mixtures were incubated for 1 h at 370C in a shaking water bath. We then plated 20 Al from each reaction mixture onto M-H agar. Colonies of surviving organisms were counted after 18 h incubation at 370C. We calculated bactericidal activity by comparingthe number of survivors in reaction mixtures containing active serum (intact complement source) to those in mixtures containing heat-inactivated serum (absence ofactive complement). Each assay was repeated at least 10 times.
Binding ofanti-Gal to S. marcescens #21 and #7 whole organisms. We examined the binding ofanti-Gal to the Serratia blood isolates, #21 and #7. Purified anti-Gal was radiolabeled to a sp act of 1.85 X 105 cpm/Mg by the lactoperoxidase-iodination procedure (21) . Serratia #21 and #7 were grown for 24 h on M-H agar, and then suspended to an Aw of 0.6 in PBS. Aliquots of 100 Ml of this suspension were put in microfuge tubes, and the bacteria collected and washed with PBS by centrifugation. We then added either 12, 120, or 390 Mg of 1251-anti-Gal to each tube and incubated the mixture for 60 minutes at 370C. The organisms were washed by repeated centrifugation in PBS and radiolabeled bound anti-Gal was counted in a gamma counter. We determined the number of CFU/ml for each test organism and calculated the number of molecules of 1251-anti-Gal bound per CFU at saturation.
To assess the specificity ofthe binding, we added a 50-fold excess of cold anti-Gal to duplicate reaction mixtures of organisms incubated with 12 Mg of '25I-anti-Gal and determined the percentages of radioactivity that were displaced. SDS-PAGE and immunoblots. Lysates and proteinase K-treated lysates of S. marcescens #21 and #7 were prepared as outlined by Hitchcock and Brown (22) ; dissolved in 2% SDS; applied to discontinuous slab gels (3% acrylamide spacer gel, 13% resolving gel) and electrophoresed at 10 mA current for 4-5 h (SDS-PAGE) (23) . The electroblotted samples were then transferred to nitrocellulose with the use of the Western blot transfer method of Burnette (24) . We first incubated the transblots for 30 min in a 1% casein solution to block nonspecific binding and then placed them for 1 h in a 1 Mg/ml solution ofanti-Gal in 1% casein. The nitrocellulose paper was then washed and incubated for 1 h with a 1:500 solution in 1% casein of an alkaline phosphatase-conjugated goat anti-human IgG (Vector Laboratories, Burlingame, CA). A naphthol substrate (1 mg/ml) and Fast Red solution (2 mg/ml) (Sigma Chemical Co.) in 50 mM Tris buffer (pH = 8) were then added and the development ofa pink color assessed visually. For time course experiments, lysates and proteinase K-treated lysates oforganisms grown in Mueller-Hinton broth for 3, 6, 12, and 24 h were prepared and examined as outlined above. As control reactions, we included transblots that were incubated with goat anti-human IgG alone (no anti-Gal). To assess the specificity ofthe anti-Gal binding to these lysates, we incubated transblots with Galserum as the blocking agent in place ofcasein, followed with biotinylated anti-Gal (20 ,g/ml) (25) and then avidin linked to alkaline phosphatase (as per Vector Laboratories). The blots were visualized as outlined above.
To examine whether anti-Gal is the major antibody in our test NHS that is specific for Serratia #21 LPS, we blotted this LPS with either 10% NHS or 10% Gal-NHS in 1% casein and then proceeded with incubations with goat anti-human IgG and then substrate solutions as outlined above.
Enzyme-linked immunosorbent assay. We used an ELISA to estimate anti-Gal binding to LPS and purified capsular polysaccharides.
Briefly, we used 75 Ml ofa 50-,gg/ml solution ofthe capsular polysaccharides to sensitize the wells ofa microtiter plate that had been previously coated with a 1 mg/ml solution of poly-L-lysine (47,000 Mr) (Sigma Chemical Co.). Nonspecific binding was blocked by 0.1% BSA in PBS with 0.02% sodium azide. Wells were then incubated for 1 h with serial twofold dilutions ofa 100-Mg/ml anti-Gal solution. After washing, 75 l1 of a 1:500 solution of alkaline phosphatase-labeled goat anti-human IgG (Vector Laboratories) were placed in each well and allowed to react for 1 h. The wells were then washed extensively and a p-nitrophenyl phosphate disodium substrate was added (2 mg/ml in 100 mM sodium bicarbonate, 10mM MgCl2, pH 9.5) (Sigma Chemical Co.). The absorbance of the solution in the plates after 15 min of incubation with the substrate was read with a 405-nm filter on an ELISA reader (2550; Bio-Rad Laboratories, Richmond, CA). The LPS ELISA was done in essentially the same way, except that the wells of the microtiter plates were not precoated with poly-L-lysine and that 75 ul of a 50-Ag/ml solution of #21 LPS sensitized these wells.
To examine the specificity ofanti-Gal binding the same experiment was done using Gal-as the blocking agent (instead of 0.1% BSA) followed by incubation with serial twofold dilutions ofa biotinylated anti-Gal solution (100 Mg/ml) (25) , and then with avidin linked to alkaline phosphatase (as per Vector Laboratories). The reaction was read as outlined above.
To find out whether anti-Gal bound to the same antigenic determinants in LPS and K antigen, we absorbed anti-Gal at 0°C for three sequential 30-min periods with S. marcescens #7 (K antigen binding) or S. marcescens #21 (LPS antigen binding). To do that, the organisms were resuspended in PBS to an A6 of 1 and then pelleted. Anti-Gal (100 Mg/ml) was then added in a volume equal to twice that of the bacterial pellet and the ability ofeach absorbed anti-Gal preparation to bind S. marcescens #7 K antigen and #21 LPS was then tested in an ELISA. C3 purification and deposition. C3 was isolated from human plasma as described by Hammer et al. (26) and was further purified as described by our laboratory (27) . C3 was radiolabeled using iodobeads (Pierce Chemical Co., Rockford, IL) as recommended by the manufacturer. Radiolabeling ofthe C3 decreased its hemolytic activity by < 10-30% (depending on the experiment) as assessed by the method of Hostetter et al. (28). C3 concentration was determined by the Pierce protein assay as recommended by the manufacturer.
C3 deposition was determined as previously described (27) . Briefly, 1 ml of strain #21 or #7 at I08-109 CFU/ml in VBS was pelleted, suspended in 200 Ml of anti-Gal 100 Mg/ml solution in PBS (NHS concentration) or in 200 Ml of PBS without anti-Gal, and incubated at room temperature for 30 min. The bacteria were then pelleted and washed three times with PBS. Serum (hypo-y or Gal-) or heat inactivated serum containing 1251-labeled C3 (sp act 1.22 X 105 for experiments with Galserum and 1.5 X 106 for experiments with hypoy serum) at a ratio of 1:44 labeled to unlabeled C3 was added to the bacterial pellet to effect a 20% final serum concentration in a total vol of 500 Ml and the mixture was incubated for 1 h at 37°C. Aliquots (108 CFU) were layered onto 1 ml of 10% BSA and the bacteria were then pelleted at 12,500 g, and washed in PBS three times. The tube tips were cut and counted in a gamma scintillation counter. All assays were performed at least twice.
Effect ofanti-Gal on the deposition of C3 and C9 on Serratia #21 LPS. Purified LPS from Serratia #21 was separated by SDS-PAGE and blotted onto nitrocellulose as previously described. The transblot was then incubated with 10% hypoy serum (in 1% casein), 10% hypoy serum + anti-Gal (100 Ag/ml), or 10% heat-inactivated hypoy serum for 1 h at room temperature (RT). The hypoy serum had normal complement activity and no antibodies against #21 LPS. The transblot was then washed extensively in PBS and incubated for 1 h at RT in a 1:100 dilution in 1% casein of affinity-purified alkaline phosphatase-linked goat anti-human C3 or C9 (E-Y Laboratories, Inc., San Mateo, CA). The transblots then were developed as outlined previously. Control reactions with only secondary antibody (and no hypoy serum) and with heat-inactivated hypoy serum (see above) were included.
To further assess the binding sites for anti-Gal and for C3 on Serratia #21 LPS, we tested the ability of anti-Gal to find its cognitive epitope on #21 LPS after C3 had bound to this antigen. The transblot of Serratia #21 LPS was first incubated with 10% hypo'y serum for 1 h, washed extensively with PBS, then incubated with anti-Gal (100 /Ag/ml in 1% casein) for 2 h, and finally incubated with goat anti-human IgG and developed as outlined above.
Molecular form of the bound C3 fragments. C3 deposition onto Serratia #21 and #7 by hypoy serum with or without anti-Gal or heatinactivated hypo-y serum with or without anti-Gal was done as outlined above, with the exception that no radiolabeled C3 was added to the serum. The C3 fragments were eluted from the organisms by treating them with 1 M hydroxylamine in 0.2M NaHCO3 containing 0.1% SDS (pH = 10.0) for 60 min at 370C (29) . The bacteria were removed by centrifugation, and the supernatant fluid containing the eluted fragments was evaluated under reducing conditions by SDS-PAGE with 10% polyacrylamide gels and transferred to nitrocellulose following methods outlined previously in this section. Native C3 was run along with these samples in order to evaluate the nature of the fragments obtained. The transblot was then incubated serially in a 1% casein solution for 30 min, then in a 1:100 solution in 1% casein of affinity purified goat anti-human C3 linked to alkaline phosphatase (E-Y Laboratories, Inc.) for 1 h at RT, washed three times with PBS, and developed as previously outlined. In addition, duplicate transblots containing identical samples to the ones above were prepared and were incubated with goat anti-human C3d linked to alkaline phosphatase (The Binding Site, San Diego, CA), in order to further evaluate the identity of the bands obtained. C9 deposition on Serratia #21 in the presence and absence ofanti-Gal. We followed the whole cell ELISA method detailed by Schlesinger et al. (29a) for C3 deposition onto Mycobacteria. Briefly, Serratia #21 was grown on M-H plates overnight and resuspended to an A6 of 0.6 in PBS. 1-ml aliquots of this suspension were placed in microfuge tubes, pelleted, and washed with PBS. The bacteria were then suspended in 200 Al of anti-Gal (100 lg/ml) in PBS or in 200 Al of PBS without anti-Gal for 30 min at room temperature. The bacteria were then pelleted and washed three times with PBS. Hypoy serum or heatinactivated hypoy serum was added to the bacterial pellet to effect a 40% final serum concentration in PBS in a total vol of 400 Ml and the mixture was incubated for 1 h at 370C. The bacteria were then collected by centrifugation, washed with PBS, and then resuspended in 1 ml of PBS. Triplicate lO0-Ml aliquots of this suspension (108 bacteria) were dispensed into the wells of a microtiter plate and were allowed to sensitize these wells for 1 h. Each well was then washed, incubated with 0.1% BSA for 30 min to block nonspecific protein binding sites, washed again with PBS, and then incubated for 2 h at RT with a 1:100 solution in 0.1% BSA ofalkaline phosphatase-linked goat anti-human C9 (E-Y Laboratories Inc.). The wells were then washed extensively and a p-nitrophenyl phosphate disodium substrate was added (2 mg/ml in 100 mM sodium bicarbonate, 10 mM MgC12, pH 9.5) (Sigma Chemical Co.). The absorbance of the solution in the plates was read with a 405-nm filter on an ELISA reader (2550; Bio-Rad) after 2 h of incubation with the substrate. The mean and standard deviation ofthe absorbance for triplicate wells of each type was calculated. Controls including bacteria that were not incubated in serum, bacteria incubated with heat-inactivated serum (see above), and wells containing no bacteria were included. Briefly, S. marcescens #21 was grown on M-H agar, pelleted, fixed with 2% paraformaldehyde and 0.1% glutaraldehyde, dehydrated with 2.3 M sucrose and then sectioned onto copper grids. The sectioned organisms were either presensitized or not with anti-Gal (100 ,g/ml) for 30 min and then incubated for 1 h with 20% hypoy serum or with heat-inactivated hypoy serum. After several washes with PBS, the organism was reacted with monoclonal anti-human C5b-9 IgG (1: 100 in PBS) for 1 h at RT and then goat anti-mouse IgG conjugated to gold (15 nm) (1:500 in PBS) for 30 min at RT.
Results
Prevalence ofbinding ofanti-Gal to Gram-negative human isolates. The prevalence ofbactena that bound anti-Gal was significantly (P = 2 X 1O-) higher among isolates from the blood of patients with Gram-negative sepsis (66%) than among those from the stools of healthy laboratory volunteers (26%) ( Table  I ). All Escherichia coli blood isolates bound anti-Gal, compared to only 40% of normal stool isolates (P = 2 x 10-4). Blood isolates of Klebsiella-Enterobacter-Serratia also bound anti-Gal significantly more often than stool isolates ofthe same species (P = 0.02). There were not enough of the other species for meaningful comparisons.
The higher prevalence of binding of anti-Gal to blood isolates as compared to stool isolates and its binding to all ofthe E. coli blood isolates raised the possibility that the antibody could enhance the ability to survive within the bloodstream ofbacteria that bound it. We began our investigation ofthis possibility by studying the effects of anti-Gal on complement-mediated killing of two representative Serratia marcescens strains that caused sepsis.
Effect of anti-Gal on the complement-mediated lysis of Serratia #21 and #7. As can be seen in Fig. 1 , S. marcescens #21 was resistant to complement-mediated killing by NHS (Ser9); however, a hypogammaglobulinemic serum that had < 5% of the normal NHS level of anti-Gal, and no detectable antibodies that bound Serratia #21, could kill it. NHS from which anti-Gal had been completely removed (Galserum) also killed Serratia #21, and to the same extent as the hypoy serum ( Fig. 1 ). When anti-Gal was added to Galor hypoy serum to a concentration equal to that in NHS (100 ,gg/ml), these sera were no longer able to kill Serratia #21 ( Fig. 1 ) (P = 0.004 for Gal-sera±anti-Gal; P = 0.001 for hypoy sera±anti-Gal). Anti-Gal blockade oflysis ofSerratia #21 therefore appeared to account for the organism's NHS resistance. Anti-Gal binds to terminal a galactosyl residues. The blocking effect of anti-Gal on NHS killing of Serratia #21 was partially reversed by a methyl galactoside but not by lactose (galactose 31,4 glucose) or sucrose (glucose a 1,2 fructose) ( Fig.  2 ), suggesting that its effect does indeed depend on binding to a galactosyl residues.
S. marcescens #7 was serum sensitive (Ser5) (Fig. 1) ; both hypoy and Galsera killed this strain as well as did whole NHS, confirming that anti-Gal did not affect its killing by NHS ( Fig. 1 ). Pathway ofcomplement activation by Serratia #21 and #7. Fig. 3 shows that killing of strain #21 by hypoy and Galsera was effected through ACP. Chelation of these sera with MgEGTA to abolish the classical pathway (CP) did not diminish their lysis of Serratia #21 organisms. When anti-Gal was added to the chelated sera, they no longer killed Serratia #21 (Fig. 3 ). Strain #21 could not be killed by Pserum (results not shown), confirming that these organisms could not be lysed through the CP.
In contrast, strain #7 was killed equally well through the CP and the ACP (Fig. 4) . Killing of strain #7 through the ACP required properdin. The CP killing of #7 was abolished when specific antibody was absorbed from Pserum or the CP in Pserum was abolished by MgEGTA chelation (Fig. 4) .
The exquisite sensitivity of strain #7 to lysis by 20% NHS 75. Figure 3 . Serum bactericidal activity against Serratia #21. We followed the same method detailed in Fig. 1 and tested Hypoy and Galsera. Hatched bars here represent sera chelated with 10 mM Mg-EGTA and therefore unable to activate the classical complement pathway. Note that Serratia #21 is partially killed by the ACP of both Hypo'y and Galsera and that the anti-Gal-mediated blockade of that killing is mediated through the ACP and is significant (P = 0.018 for chelated Hypo'y with/without anti-Gal).
made it difficult to assess whether anti-Gal was augmenting its killing. Under complement limiting conditions (10% final serum concentration), however, the addition of anti-Gal to MgEGTA-chelated hypoy serum resulted in a modest but significant increase in ACP killing (P = 0.03 for chelated 10% hypo'y sera±anti-Gal) ( Fig. 5 ).
Binding ofanti-Gal to S. marcescens #21 and #7. The opposite effects of anti-Gal on the ACP-mediated lysis of the two Serratia led us to investigate whether there were differences in the number of binding sites for anti-Gal on the two strains. Serratia #7 did bind significantly more anti-Gal molecules . We followed the same method detailed in Fig. 1 except that reaction mixtures also contained a test carbohydrate inhibitor (a methyl galactoside, # lactose, or sucrose) at a 100 mM final concentration.
Open bars represent Hypo-y sera without added anti-Gal. Hatched bars represent Hypoy sera with anti-Gal. Note that only a methyl galactoside (but not , lactose or sucrose) was able to partially inhibit the blocking effect of anti-Gal on ACP-mediated killing of Serratia #21 by Hypoy sera.
4-L NHS Hypoy
P-Abs P Figure 4 . Serum bactericidal activity against Serratia #7. We followed the same method detailed in Fig. 1 . We tested the following sera: NHS, Hypo-y sera, properdin deficient (P-) sera and P-absorbed with strain #7 (Abs P-). Hatched bars represent sera chelated with Mg-EGTA. Note that strain #7 is serum sensitive and killed by both the ACP and the CP. The ACP kill is highly dependent on properdin (minimal kill in P MgEGTA-chelated sera). The CP kill is dependent on specific antibody (minimal kill in absorbed P-sera). than did Serratia #21 (Fig. 6 ). The binding of '251-anti-Gal to both strains could be completely displaced by a 50-fold excess of cold anti-Gal (Table II ). An alternative explanation for the opposite effects of anti-Gal could be that it bound to different structures on the surfaces ofthe two strains. Figs. 7 and 8 show that anti-Gal bound to S. marcescens #21 LPS (regularly spaced middle and high Mr * We followed the method detailed in Fig. 6 except that 12 Ag of anti-Gal was added to the organisms. We then added a 50-fold excess of cold anti-Gal to duplicate reaction mixtures and counted these similarly using a gamma counter. bands), but not to S. marcescens #7 LPS or outer membrane proteins. We obtained identical binding patterns to the two Serratia when the samples were treated with proteinase K (not shown), indicating that anti-Gal did not bind to outer membrane proteins. Anti-Gal binding ofSerratia #21 LPS varied in intensity as the number of repeating LPS units changed; no binding to low M, LPS components or to core LPS was detected ( Fig. 7) . The pattern of binding of anti-Gal to Serratia #21 was not a function of when the strain was sampled in its growth cycle; the lack ofbinding ofanti-Gal to Serratia #7 was also not a function of growth time (Fig. 8, A and B) . In addi- Anti-Gal (jsg) Figure 6 . Binding ofanti-Gal to Serratia #21 and #7 whole organisms. Affinity-purified anti-Gal was radiolabeled to a sp act of 1.85 X 10s cpm/,ug by the lactoperoxidase iodination procedure. Serratia #21 and #7 were grown for 24 h on MH agar, suspended to an Aw of 0.6 in PBS. Aliquots of 100 Ml ofthis suspension were put in microfuge tubes, and the bacteria collected and washed with PBS by centrifugation. 125I-anti-Gal (12, 120, or 390 Mg) was then added and the mixture incubated for 60 min at 37°C. The organisms were washed by repeated centrifugation in PBS and radiolabeled bound anti-Gal was counted in a gamma counter. We determined the number ofCFU/ml for each organism and calculated the number of molecules of '25Ianti-Gal bound per CFU. As shown in this figure, anti-Gal binds to both Serratia #21 and #7 but significantly more to Serratia #7 (P < 0.01 for 390 ;ig anti-Gal binding points). 11 .. ..f. Figure 7 . Immunoblot with anti-Gal of SDS-PAGE-separated LPS of Serratia #21 and #7. Samples were dissolved in 2% SDS, applied to discontinuous slab gels (3% acrylamide spacer gel, 13% resolving gel), electrophoresed at 10 mA current for 4-5 h and transferred to nitrocellulose overnight. The transblot was reacted with anti-Gal (100 Mg/ml), and then incubated with an alkaline phosphatase-conjugated goat anti-human IgG. Note that Serratia #21 LPS bound anti-Gal but Serratia #7 LPS did not. Fig. 7 . Note that Serratia #21 bound anti-Gal at all time points but that Serratia #7 did not.
Regulation ofAlternative
tion, the binding ofanti-Gal to #21 LPS appeared to be specific as evidenced by unaltered binding of biotinylated anti-Gal to #21 LPS by Western blot when Galserum was used instead of 1% casein to block nonspecific binding sites (results not shown). The lipopolysaccharides of Serratia #21 and #7 differed in their ability to bind anti-Gal and other antibodies in NHS. Anti-Gal was the only antibody in NHS that bound #21 LPS, as Galserum did not bind to #21 LPS by Western blot (results not shown). In contrast, Serratia #7 LPS did not bind anti-Gal. However, there was strong binding of both NHS and Galserum to #7 LPS indicating the presence of specific LPS antibodies in NHS that are not anti-Gal (results not shown).
Although the LPS of Serratia #7 did not bind anti-Gal ( Figs. 7, 8 , and Fig. 9 ), its purified capsular polysaccharide did (Fig. 10) . In contrast, the capsular polysaccharide of Serratia #21 did not bind anti-Gal (Fig. 10 ), but its LPS did (Figs. 7, 8,  and 9 ). This means that the digalactose structure to which anti-Gal binds is present in different organelles (LPS or capsular polysaccharide) on these two Serratia. The results obtained using Galto block nonspecific binding sites were identical to Reciprocal Dilution of anti-Gal (1092) Figure 9 . Anti-Gal binding to #21 LPS (oo) and #7 LPS (aa) by ELISA. Binding of #21 LPS to anti-Gal absorbed with Serratia #7 whole organism (o -0) by ELISA. We followed the same method outlined in Fig. 9 except that the wells ofthe microtiter plates were not precoated with poly-L-lysine. Note that only Serratia #21 LPS binds to anti-Gal. Anti-Gal loses its ability to bind to #21 LPS when it is preabsorbed with Serratia #7. This again suggests that the specificity of anti-Gal on these two organisms is similar.
those we got using 0.1% BSA as the blocking agent (not shown). This shows that anti-Gal was bound specifically to #7 capsular polysaccharide and #21 LPS. Anti-Gal is a polyclonal antibody, and different clonal populations could be binding to the two Serratia and producing opposite ACP effects. Absorptions of anti-Gal with Serratia #21 or #7 not only abolished binding to the absorbing organisms' LPS or K antigen, respectively, but also abolished bind- bacteria by ELISA. The capsular polysaccharides (50 ug/ml) sensitized the wells of a microtiter plate that were previously coated with poly-L-lysine (47,000 Mr). Wells were incubated for 1 h with serial twofold dilutions of a 100-,ug/ml anti-Gal or absorbed anti-Gal solutions and then reacted with goat anti-human IgG conjugated to alkaline phosphatase. Note that only Serratia #7 capsular polysaccharide (and not Serratia #21 capsule) bound anti-Gal. Also note that anti-Gal absorbed with Serratia #21 whole bacteria looses its ability to bind Serratia #7 capsule, suggesting a shared anti-Gal specificity on these two organisms.
Regulation ofAlternative Complement Pathway by Anti-Gal 1229
A ing to the other organisms' outer membrane antigen (Figs. 9 and 10). Thus the same antibody within the anti-Gal polyclonal pool appeared to be binding to both Serratia, but to different outer membrane antigens.
Effect ofanti-Gal oqdeposition ofC3 and C9 onto Serratia #21 LPS. Binding ofanti-Gal to Serratia #21 might block ACP activation by several mechanisms. It might occupy the LPS C3b binding site or sterically hinder the binding of C3b to neighboring LPS sites. In either event, the number of molecules of C3 bound to Serratia #21 would decrease. Anti-Gal also might accelerate the decay of bound C3b or decrease the affinity of C3b for factor B, thereby interfering with effective assemblage of the ACP C3 convertase. Alternatively, it might redirect bound C3b to sites further away from the bacterial outer membrane, thereby making it more difficult for the MAC to find sites into which it could embed, or change the molecular configuration of the MAC. Effect ofanti-Gal on the number ofC3 molecules deposited onto Serratia #21 and #7. We used two different 125I-C3 preparations to quantitate C3 deposition onto both Serratia by Galand Hypoy sera, respectively. Both C3 preparations were radiolabeled using iodobeads from Pierce, and both had a poorly radiolabeled ,3 chain (not shown). However, these two preparations lost only 10-30% of normal C3 hemolytic activity (28).
The number of molecules ofC3 deposited specifically onto Serratia #21 by hypoy or Gal-MgEGTA-chelated sera was similar in the absence and presence of anti-Gal (Table III) . Anti-Gal also had very little effect on the number ofmolecules ofC3 deposited by either serum onto Serratia #7, even though Serratia #7 bound significantly more molecules of anti-Gal than Serratia #21. Note that the number of molecules of C3 deposited onto strain #7 and onto strain #21 by hypoy MgEGTA-chelated serum was less than that deposited by Gal-MgEGTA-chelated serum suggesting that antibodies other than anti-Gal in the latter serum were contributing to ACP C3 with 20 sg of anti-Gal for 30 min at room temperature. We then added to the bacteria either 20% MgEGTA-chelated serum (Galor Hypoy) or heat-inactivated (A&) MgEGTA-chelated serum that contained '251-labeled C3 at a ratio oflabeled to unlabeled C3 of 1:44 and incubated them for I h at 37°C. The specific activity of the C3 was 1.22 X 10' for experiments with Galserum and 1.5 x 106 for those with Hypoy serum. After pelleting the bacteria, we washed them in PBS/0.1% SDS and resuspended them in PBS. We counted aliquots that contained IO' CFU in a gamma scintillation counter and determined the number of bound C3 molecules per CFU by multiplying the number of 125I-C3 molecules deposited by the dilution factor of 45. LPS was separated by SDS-PAGE and transferred to nitrocellulose as detailed in Fig. 7 and then reacted with 10% Hypoy sera with and without anti-Gal. The
Hypo'y serum used had no anti-LPS antibodies against strain #21 and * had very low levels of A B anti-Gal antibody (< 5% NHS concentration). C3 binding to the SDS-PAGE-separated #21 LPS was visualized using goat anti-human C3 conjugated to alkaline phosphatase. Molecular weight markers (indicated by the arrows) are from top to bottom: 110 kD, 84 kD, 47 kD, 33 kD, 24 kD, and 16 kD. Note the similar binding pattern of C3 to the high and middle Mr LPS components in the presence (A) and absence (B) of anti-Gal. deposition onto these two stains. The number ofC3 molecules bound nonspecifically in heat-inactivated sera (A Gal-and A Hypo'y) differed in the two sera and between the two Serratia but averaged around 30% ofthose bound to untreated Gal-and Hypo'y sera.
Site ofbinding ofC3 and C9 on Serratia #21 in thepresence and absence ofanti-Gal. Both C3 (Fig. 1 1) and C9 (Fig. 12) , as detected by their antibodies, bound to the same LPS molecules as did anti-Gal, and their binding was not changed or inhibited by the presence of anti-Gal. There was no C3 nor C9 binding when heat-inactivated serum was used ( Fig. 13 for C3 ; results not shown for C9). We followed the method detailed in Fig. 11 except that we visualized C9 binding to the SDS-PAGE-separated LPS with goat anti-human C9 conjugated to alkaline phosphatase. Note the similar binding pattern of C9 to the #21 LPS in the presence (A) B and absence (B) of anti-Gal. lowing for C3 to bind first), followed by incubation with anti-Gal, did not abolish the binding of anti-Gal to its cognitive epitope on #21 LPS (Fig. 13 ). This indicates that anti-Gal and C3 have distinct binding sites on #21 LPS. Anti-Gal therefore does not compete for the same receptor as C3 on #21 LPS and also does not seem to interfere with the deposition of C9 onto this antigen. Effect ofanti-Gal on the molecularform ofbound C3fragments on Serratia #21 and #7. SDS-PAGE analysis of the C3 fragments released from strain #21 and strain #7 after incubation with hypoy MgEGTA-chelated sera showed that C3b (a chain M, 105,000, ,3 chain M, 75,000), iC3b (a' chain Mr 67,000 and 40,000, and ,3 chain Mr 75,000) and a lower molecular weight fragment (Mr 16,000) were released from Serratia #21 and from Serratia #7 (Fig. 14) . The major fragment released from strain #21 was iC3b. The 16-kD fragment was also clearly visible. The a chain of C3b was minor.
Anti-Gal had no effect on the fragmentation pattern of C3 onto these two bacteria; identical patterns were observed in the presence and absence of anti-Gal. Also note also that Serratia #21 and #7 had very similar C3 fragmentation patterns when incubated in hypoy serum containing anti-Gal, despite the opposite effects that this antibody had on the complement-mediated lysis of these bacteria.
To further evaluate the nature ofthe 16-kD C3 degradation product, identical transblots were incubated with goat anti-human C3d. This latter antibody bound the 16-kD band, indicating that this product may be a lower molecular weight fragment of C3d (results not shown). to this antigen, indicating distinct epitopes for anti-Gal and C3 on #21 LPS. Lane B represents Serratia #21 LPS incubated with anti-Gal (100 gg/ml) for 2 h, then incubated with goat anti-human IgG and developed. Note that anti-Gal binds to Serratia #21 LPS under these experimental conditions and in a pattern similar to that shown in lane A. Lane C represents the same experiment as in Panel A except that goat anti-human C3 was used as secondary antibody. Note that C3 binds to Serratia #21 LPS under these experimental conditions. Lane D represents Serratia #21 LPS incubated with 10% heat-inactivated Hypoy serum, then with anti-Gal, and finally with goat anti-human C3. Note that C3 does not bind to #21 LPS when heat-inactivated serum is used. Molecular weight markers are from top to bottom: I 10 kD, 84 kD, 47 kD, 33 kD, 24 kD, and 16 kD.
A Al B Bi C3 C Cl D Di Figure 14 . Molecular form of the bound C3 fragments. C3 deposition on Serratia #21 and #7 was done as outlined in the method in Table  III except that the organisms were incubated with Hypo serum without added radioactive C3. The C3 fragments were eluted from the organisms by treating them with 1 M hydroxylamine in 0.2 M NaHCO3 containing 0.1% SDS (pH 10.0) for 60 min at 370C. The bacteria were removed by centrifugation, and the supernatant fluid containing the eluted fragments was evaluated under reducing conditions by SDS-PAGE with 10% polyacrylamide gels and transferred to nitrocellulose. The transblots were incubated in 1% casein for 30 min, followed by incubation in a 1:100 dilution in 1% casein ofgoat anti-human C3 linked to alkaline phosphatase and then were developed. Molecular C9 deposition on Serratia #21 in the presence and absence ofanti-Gal. Fig. 15 reveals that C9 is deposited onto Serratia #21 whole organism when incubated with hypoy serum alone or with hypoy serum with anti-Gal. No C9 is deposited when the serum is heat-inactivated (hatched bars). This experiment shows that anti-Gal does not inhibit the deposition of C9 onto Serratia #21 even though this antibody blocks the killing of Serratia #2 1. MACformation on Serratia #21 by hypoy sera in the presence and absence ofanti-Gal. Fig. 16 shows representative electron micrographs ofSerratia #21 incubated with hypoy serum with anti-Gal (A) or heat-inactivated hypoy serum with anti-Gal (B). Identical binding patterns were obtained with organisms not presensitized with anti-Gal (results not shown). MAC was deposited onto Serratia #21 in the presence of anti-Gal ( Fig. 16 A) despite the fact that this antibody completely blocks the complement-mediated killing ofthis strain. Note that there is very low nonspecific binding of the monoclonal antibody (recognizing the MAC neoantigen) to Serratia #21 when the organism is incubated in heat-inactivated serum (Fig. 16 B) .
Anti-Gal therefore does not inhibit the assembly of a MAC on the surface ofSerratia #21, even though anti-Gal blocks the complement-mediated lysis of this strain.
Discussion
The findings we report here challenge the traditional role of antibody, that of a molecule that protects the host from bacterial invasion. The human anti-Gal IgG, a ubiquitous high titered natural antibody, does not appear to provide a protected site for C3 deposition, nor does it initiate immune lysis. It can in fact block ACP-mediated lysis when it finds its epitope on the lipopolysaccharide of Serratia #21.
That anti-Gal may play a role in the pathogenesis ofGramnegative sepsis is suggested by the fact that this antibody binds significantly more often to Enterobacteriaceae isolated from the blood of patients with sepsis than to Enterobacteriaceae recovered from the stool of healthy laboratory volunteers. Because these volunteers work in a hospital setting, their stool flora may be more representative of hospital flora than street A Figure 16 . Detection of the MAC on Serratia #21 by electron microscopy. Sectioned organisms were presensitized with anti-Gal (100 gg/ml) for 30 min and then incubated for 1 h with 20% Hypoy serum (Panel A, X50,000) or with heat-inactivated Hypoy serum (Panel B, X37,000). The organism was then reacted with a monoclonal anti-human C5b-9 and then with goat anti-mouse IgG conjugated to gopld (15 nm). The monoclonal antibody used binds to a neoantigen on the C5b-9 complex (MAC) of human complement. Note that this monoclonal antibody binds to Serratia #21 in the presence of anti-Gal, indicating that a MAC was formed on the surface of the bacteria under these conditions. I I 0.0 flora. The difference we found between the stool's and the blood isolates' prevalence of binding to anti-Gal therefore might be even more pronounced if we had studied individuals that work in the community. The ability of Escherichia coli to bind anti-Gal seems to be a necessary but insufficient attribute for sepsis to occur; binding of anti-Gal by other enteric organisms also seems to enhance their ability to cause sepsis.
If binding of anti-Gal is an important factor in the pathogenesis of sepsis, then anti-Gal must interfere with normal host defense mechanisms. We chose to examine the effect of anti-Gal on a complement-mediated clearance mechanism, immune lysis, since blocking of immune lysis by IgG (31) had been described previously. Unlike other serum IgG antibodies, anti-Gal does not activate the classical complement pathway when it binds the bacteria we studied, and its effect appears to be exclusively on the ACP. It seems reasonable to assume, then, that anti-Gal plays an immunopathogenic role mostly in the "nonimmune" host that has not synthesized other specific antibodies.
Specific blocking antibodies have been found before in NHS (31, 32) ; however, these earlier studies did not define the specificity of the blocking IgG nor did they examine the complement pathway that was involved. When we examined the effect of anti-Gal on two representative S. marcescens human isolates, we found that anti-Gal did not increase the number of C3 molecules deposited by the ACP in hypogammaglobulinemic serum, nor did it change the degradation pattern of the covalently bound C3b fragments on these organisms. We therefore would not have expected anti-Gal to modulate ACP-mediated immune effector mechanisms on these two Serratia, and that appeared consistent with its modest enhancement of ACP lysis of a Ser' Serratia, #7, which also bound other IgG in NHS. Anti-Gal, however, had a major effect on the ACP-mediated lysis of Ser' Serratia, #21, which did not bind any other IgG to its LPS. Anti-Gal completely blocked the ability of serum to kill this organism and was solely responsible for the normal serum resistance of the bacteria. The mechanism of blockade by anti-Gal remains unclear. It did not change the number of molecules of C3 deposited onto Serratia #21. Approximately 13,000 molecules of C3 were deposited specifically on Serratia #21 by hypoy serum, both in the presence and absence of anti-Gal. Wright et al. (33) showed that only two terminal membrane attack complexes were sufficient to cause disruption of both the inner and outer membranes of E. coli, so the number of C3 molecules deposited onto Serratia #21 should have been more than enough to support lysis unless they completely failed to assemble membrane attack complexes.
The number of C3 molecules deposited on Serratia #21 and #7 by heat-inactivated Galand Hypoy sera differed for each organism and was much higher in A Galthan in A Hypoy sera, for reasons that are unclear to us at this point. The somewhat higher than reported percent ofC3 molecules deposited in heat-inactivated sera in our experiments (30% of total C3 deposited compared to 10-20% in the literature) may have obscured small but important differences between C3 binding in the presence and absence ofanti-Gal. However, the C3 molecules deposited onto Serratia #21 by hypoy serum resulted in partial killing of the bacteria, showing that they were able to initiate lysis in the absence of anti-Gal, but they were completely ineffective in the presence ofthis antibody. This was not because anti-Gal changed the site ofbinding ofC3 (LPS) or the molecular form of its fragments on Serratia #21 (mostly iC3b, but also a fragment of C3d and minor amounts of C3b). Nor did anti-Gal inhibit C9 deposition or MAC formation on the organism.
It remains possible that anti-Gal may be "relocating" the MAC to a nonlytic site on the LPS ofSerratia #21, perhaps by occupying the "preferred" site of C3b binding. This would imply that the many OH residues that are available on this LPS are not equivalent in their influence on the subsequent generation of an "effective" MAC by C3b molecules that bind to them. Another possibility would be that anti-Gal may affect the stability of the MAC on the surface of the organism, perhaps by occluding the insertional site of the MAC. Ineffective deposition of the C5b-9 complex in the presence of specific antibody had been reported for serum resistant strains of Salmonella minnesota (34, 35) and Neisseria gonorrhoeae (36) . However, the role, ifany, ofthe antibody in NHS in the ineffective deposition ofthe MAC onto these bacteria was not investigated and neither was the complement pathway through which these bacteria were killed.
The two Serratia also differed in the sites to which they bound anti-Gal. This could have been because they bound different populations of anti-Gal. Methyl a-galactoside, but not lactose or sucrose, inhibited the blocking of ACP killing of strain #21 by anti-Gal, showing that the specificity of anti-Gal on strain #21 was, as expected, for a structure similar to methyl a-galactoside. There is, however, a considerable diversity in the recognition of a-linked galactose epitopes by human natural antibodies; a 1,3, a 1,2, a 1,4, and a 1,6 antibody specificities have all been described (37) . The highest affinity of anti-Gal is for galactose a 1,3 galactose; its affinity decreases when it binds galactose a-linked to other carbons in the order ofa 1,2, then a 1,6, and then the almost inactive a 1,4 bond (37) . The fact that absorbing anti-Gal with either Serratia abolished its binding to the other shows that the two strains do share antigenic specificities for anti-Gal. The antibody found its antigen within different carbohydrate organelles, however, implying that there are differences in the chemical structures that flank the anti-Gal binding sites. The acidic nature of most K antigens made by Enterobacteriaeceae and the neutral nature of their LPS (38) would provide for such a difference. Defining the exact structures of anti-Gal binding sites on strains #21 and #7 should provide information about the chemical nature of bacterial ACP regulatory sites.
The anti-Gal that bound LPS could have been ofan isotype that has little complement activating potential, whereas that which bound capsular polysaccharide could have been of a different isotype. Human anti-Gal is composed of all IgG subclasses with IgG2 > IgGl > IgG3 > IgG4 (39), so this seems an unlikely explanation and we did not pursue it.
Serratia #21 had mostly iC3b and only minor amounts of C3b on its surface when incubated in hypoy serum, and yet was partially lysed. The more sensitive Serratia #7 incubated in hypoy serum deposited mostly C3b and iC3b onto its surface. Both strains also bound a fragment of C3d. The addition of anti-Gal had no effect on the C3b degradation patterns on either Serratia. This emphasizes that anti-Gal does not provide an antibody-facilitated site for C3 activation.
Why some C3b molecules are degraded to iC3b, whereas others are further degraded to C3d, is not entirely clear. C3d binds CR2 in B lymphocyte membranes and initiates an antibody response (40) . Different pneumococcal capsular polysac-charides bind different amounts of C3d, and these differences are related to differences in their immunogenicity (41) . Serotypes that are highly immunogenic in man have abundant C3d on their surfaces; less immunogenic serotypes do not (42) . This would seem to indicate that the fate ofbound C3b may depend upon the exact nature of the OH radical to which its C3d domain has bound.
A low M, fragment of C3b (16,000) that may represent a fragment of C3d was eluted from Serratia #21 that had been incubated in hypoy serum. It would be interesting to learn whether this fragment can bind CR2 and promote further production of blocking anti-Gal, thereby perpetuating the organism's evasion of host defense mechanisms.
The major C3b degradation product on Serratia #21, when incubated with or without anti-Gal, was iC3b which can bind CR3 receptors on phagocytes. Studies that examine the effect of anti-Gal on opsonophagocytosis of Serratia #21 by polymorphonuclear leukocytes are in progress; they should clarify whether this antibody can also interfere with this immune effector mechanism.
A dual role as both agonist and antagonist of complement activation on bacterial surfaces has been reported previously for IgG and IgA molecules of different specificities (27, 36, 43, 44) . How and when an Ig molecule plays a blocking rather than a permissive role is not understood. Our data suggest that it may be largely a function of where the antibody binds on the bacterial outer membrane.
Anti-Gal participates in the clearance ofsenescent or pathologically deformed erythrocytes that surface expose cryptic galactosyl structures (45, 46) . Anti-Gal's blocking ofACP activation may serve to protect man from continuous activation of complement on the surface ofthese and potentially other senescent human cells. Conversely, anti-Gal appears to play a detrimental role in the pathogenesis of certain autoimmune disorders, including thyroiditis, IgA nephropathy, and Henoch-Shoenlein purpura (16, 47) . Our findings suggest that anti-Gal also may play a role in the intravascular survival of certain Gram-negative bacteria and raise intriguing questions about the effect ofthis ubiquitous molecule on other immune effector mechanisms, including opsonophagocytosis and T and B cellmediated events.
